TTLL4 glutamyltransferase is a therapeutic target for NPM1-mutated acute myeloid leukemia
Alexandra Schurer, Humaira Ilyas, Maxim I. Maron, Subray S. Hegde, Melissa R. Leyden, Irene Mariam Roy, Rotila Hyka, Lucas Dada, Jeffrey Shabanowitz, Donald F. Hunt, Ellen Angeles, Victor Morell, Benjamin M. Lorton, Shira G. Glushakow-Smith, Daniel K. Borger, , David Shechter
This study identifies TTLL4 as a therapeutic target in NPM1-mutated AML by showing its role in stabilizing NPM1c and promoting differentiation block, with a small molecule inhibitor demonstrating efficacy.
bioRxiv · Apr 7, 2025 · PreprintCancer Biology